Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC, a biotech firm specializing in mental health treatment development, has strategically refocused its business by appointing a new CEO, Anthony Tennyson, and shifting towards healthcare, particularly in treating mental health and substance use disorders. The company has streamlined its operations by divesting its industrial polymer division and raising £1.8 million for growth. They’ve also initiated a collaboration with Awakn Life Sciences Corp. to co-develop therapeutics for trauma-related disorders like PTSD, and are strengthening their IP portfolio with new patent applications.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
